Literature DB >> 29511877

The use of acellular dermal matrix in immediate two-stage prosthetic breast reconstruction provides protection from postmastectomy radiation therapy: a clinicopathologic perspective.

Tae Hwan Park1, Soon Won Chung2, Seung Yong Song2, Dae Hyun Lew2, Tai Suk Roh2, Dong Won Lee3.   

Abstract

Although there is ample evidence showing that radiation therapy increases the risk of complications of breast reconstruction, the efficacy of human acellular dermal matrix (CGCryoDerm®) in immediate tissue expander breast reconstruction in the setting of postmastectomy radiation therapy has not been fully elucidated. In this study, we report our institutional experience with pertinent refined surgical technique, and determine whether acellular dermal matrices have a protective effect in this increasingly prevalent clinical setting. Twenty-six patients who underwent immediate two-stage breast reconstruction in the setting of postmastectomy radiation therapy with at least 2 years of follow-up were retrieved. Fifteen patents were reconstructed with ADM, whereas 11 patients were reconstructed without ADM. The occurrence of complications was assessed according to the reconstruction type (with ADM vs without ADM). Furthermore, in patients reconstructed with ADM (n = 15), immunohistochemistry was performed to analyze the breast capsule with ADM compared with that without ADM in the same patient, according to the expression of alpha-smooth muscle actin (α-SMA). The occurrence of complications was significantly associated with the reconstruction type (with ADM vs. without ADM, p = 0.015). On the basis of the results of α-SMA staining, α-SMA+ myofibroblasts were relatively highly expressed throughout the breast capsule without ADM. On the contrary, α-SMA+ myofibroblasts present at the breast capsule adjacent to the ADM were scarce and irregularly scattered. Use of an acellular dermal matrix may be recommended to patients who are concerned about complications after immediate two-stage breast reconstruction in the setting of postmastectomy radiation therapy.

Entities:  

Mesh:

Year:  2018        PMID: 29511877     DOI: 10.1007/s10856-018-6036-6

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  12 in total

1.  AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation.

Authors:  Maurice Y Nahabedian
Journal:  Plast Reconstr Surg       Date:  2009-12       Impact factor: 4.730

Review 2.  Acellular dermal matrix in breast reconstruction in the setting of radiotherapy.

Authors:  Ron Israeli; Randall S Feingold
Journal:  Aesthet Surg J       Date:  2011-09       Impact factor: 4.283

3.  Treatment of Pseudoangiomatous Stromal Hyperplasia of the Breast: Implant-Based Reconstruction with a Vascularized Dermal Sling.

Authors:  Bok Ki Jung; Ji Hae Nahm; Dae Hyun Lew; Dong Won Lee
Journal:  Arch Plast Surg       Date:  2015-09-15

4.  What Is the Optimum Timing of Postmastectomy Radiotherapy in Two-Stage Prosthetic Reconstruction: Radiation to the Tissue Expander or Permanent Implant?

Authors:  Peter G Cordeiro; Claudia R Albornoz; Beryl McCormick; Clifford A Hudis; Qunying Hu; Alexandra Heerdt; Evan Matros
Journal:  Plast Reconstr Surg       Date:  2015-06       Impact factor: 4.730

5.  Factors affecting complications in radiated breast reconstruction.

Authors:  Ivo A Pestana; Douglas C Campbell; Gaurav Bharti; James T Thompson
Journal:  Ann Plast Surg       Date:  2013-05       Impact factor: 1.539

6.  A Comparison of Dermal Autograft and Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: Long-term Aesthetic Outcomes and Capsular Contracture.

Authors:  Michael P Lynch; Michael T Chung; Brian D Rinker
Journal:  Ann Plast Surg       Date:  2015-06       Impact factor: 1.539

7.  ASPS clinical practice guideline summary on breast reconstruction with expanders and implants.

Authors:  Amy Alderman; Karol Gutowski; Amy Ahuja; Diedra Gray
Journal:  Plast Reconstr Surg       Date:  2014-10       Impact factor: 4.730

Review 8.  Acellular dermal matrix in irradiated tissue expander/implant-based breast reconstruction: evidence-based review.

Authors:  Mark W Clemens; Steven J Kronowitz
Journal:  Plast Reconstr Surg       Date:  2012-11       Impact factor: 4.730

9.  Acellular dermal matrix reduces capsule formation in two-stage breast reconstruction.

Authors:  Karan Chopra; Bryan Buckingham; Jamil Matthews; Jennifer Sabino; Kashyap K Tadisina; Ronald P Silverman; Nelson H Goldberg; Sheri Slezak; Devinder P Singh
Journal:  Int Wound J       Date:  2016-08-15       Impact factor: 3.315

10.  Comparison of Histological Characteristics of Acellular Dermal Matrix Capsules to Surrounding Breast Capsules in Acellular Dermal Matrix-Assisted Breast Reconstruction.

Authors:  Deborah Yu; Kasandra R Hanna; Robin D LeGallo; David B Drake
Journal:  Ann Plast Surg       Date:  2016-05       Impact factor: 1.539

View more
  3 in total

1.  Direct comparison of CGCRYODERM and DermACELL in the same patient for outcomes in bilateral implant-based breast reconstruction: a retrospective case series.

Authors:  Sungmi Jeon; Jeong Hyun Ha; Ung Sik Jin
Journal:  Gland Surg       Date:  2021-07

2.  Postmastectomy Radiation Therapy in the Setting of Two-Stage Retropectoral Implant-Based Breast Reconstruction: Should It be Delivered Before or After Implant Exchange? A Retrospective Analysis on 183 Patients.

Authors:  Barbara Cagli; Marco Morelli Coppola; Federica Augelli; Francesco Segreto; Stefania Tenna; Annalisa Cogliandro; Paolo Persichetti
Journal:  Aesthetic Plast Surg       Date:  2022-07-19       Impact factor: 2.708

3.  Hypofractionated Radiotherapy With Volumetric Modulated Arc Therapy Decreases Postoperative Complications in Prosthetic Breast Reconstructions: A Clinicopathologic Study.

Authors:  Seung Yong Song; Jee Suk Chang; Kenneth L Fan; Mi Jung Kim; Hsien Pin Chang; Dae Hyun Lew; Tai Suk Roh; Hyun Roh; Yong Bae Kim; Dong Won Lee
Journal:  Front Oncol       Date:  2020-11-17       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.